NASDAQ:ILMN Illumina (ILMN) Stock Price, News & Analysis $124.39 -5.37 (-4.14%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$123.87â–Ľ$130.8050-Day Range$105.28â–Ľ$135.9052-Week Range$89.00â–Ľ$162.16Volume1.42 million shsAverage Volume2.06 million shsMarket Capitalization$19.82 billionP/E RatioN/ADividend YieldN/APrice Target$151.05 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Illumina alerts: Email Address Illumina MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside21.4% Upside$151.05 Price TargetShort InterestHealthy2.64% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.80Based on 16 Articles This WeekInsider TradingN/AProj. Earnings Growth15.68%From $3.89 to $4.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.73 out of 5 starsMedical Sector44th out of 910 stocksAnalytical Instruments Industry2nd out of 26 stocks 3.3 Analyst's Opinion Consensus RatingIllumina has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 12 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst CoverageIllumina has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Illumina's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.64% of the outstanding shares of Illumina have been sold short.Short Interest Ratio / Days to CoverIllumina has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Illumina has recently decreased by 9.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIllumina does not currently pay a dividend.Dividend GrowthIllumina does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIllumina has received a 61.69% net impact score from Upright. Illumina seems to create the most significant positive value in categories "Taxes", "Jobs", and "Physical diseases". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Laboratory reagents", "DNA sequencers", and "Laboratory reagents for cells" products. See details.Environmental SustainabilityThe Environmental Impact score for Illumina is -1.11. Previous Next 3.2 News and Social Media Coverage News SentimentIllumina has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Illumina this week, compared to 14 articles on an average week.Search Interest30 people have searched for ILMN on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Illumina to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Illumina insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.17% of the stock of Illumina is held by insiders.Percentage Held by Institutions89.42% of the stock of Illumina is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Illumina's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Illumina are expected to grow by 15.68% in the coming year, from $3.89 to $4.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Illumina is -15.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Illumina is -15.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIllumina has a P/B Ratio of 13.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Illumina's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Illumina Stock (NASDAQ:ILMN)Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Read More ILMN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ILMN Stock News HeadlinesSeptember 5 at 1:45 AM | wsj.comIllumina’s Antitrust VindicationSeptember 5 at 1:45 AM | markets.businessinsider.comIllumina: Persisting Challenges and Underperform Rating Despite Positive Legal DevelopmentSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... September 3, 2024 | ft.comEU’s top court sides with Illumina over probe into $8bn Grail acquisitionSeptember 3, 2024 | markets.businessinsider.comIllumina Not To Pay EUR 432 Mln EU Fine Over Grail Deal After Favorable European Court VerdictSeptember 3, 2024 | benzinga.comEuropean Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M FineSeptember 3, 2024 | seekingalpha.comIllumina wins legal battle over Grail deal in EU; avoids €432M fineSeptember 3, 2024 | msn.comIllumina Wins EU Top Court’s Support in Grail AcquisitionSeptember 7, 2024 | Sasco Gold LLC (Ad)Say Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... September 3, 2024 | prnewswire.comEuropean Court of Justice rules in favor of Illumina in jurisdictional appealSeptember 3, 2024 | reuters.comEU top court backs Illumina fight against EU probe into Grail dealAugust 30, 2024 | americanbankingnews.comIllumina (NASDAQ:ILMN) Lifted to Buy at ArgusAugust 29, 2024 | prnewswire.comResults of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision OncologyAugust 29, 2024 | msn.comArgus Research Upgrades Illumina (ILMN)August 29, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Illumina (NASDAQ:ILMN)August 28, 2024 | benzinga.comHere's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth TodayAugust 28, 2024 | americanbankingnews.comIllumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Moderate Buy" by AnalystsAugust 28, 2024 | americanbankingnews.comAnalysts Set Illumina, Inc. (NASDAQ:ILMN) Target Price at $151.10See More Headlines Receive ILMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ILMN CUSIP45232710 CIK1110803 Webwww.illumina.com Phone(858) 202-4500Fax858-202-4766Employees9,300Year Founded1998Price Target and Rating Average Stock Price Target$151.05 High Stock Price Target$242.00 Low Stock Price Target$100.00 Potential Upside/Downside+21.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage23 Analysts Profitability EPS (Most Recent Fiscal Year)($8.15) Trailing P/E RatioN/A Forward P/E Ratio31.98 P/E GrowthN/ANet Income$-1,161,000,000.00 Net Margins-68.73% Pretax Margin-68.53% Return on Equity3.08% Return on Assets1.60% Debt Debt-to-Equity Ratio1.04 Current Ratio1.11 Quick Ratio0.86 Sales & Book Value Annual Sales$4.43 billion Price / Sales4.47 Cash Flow$3.39 per share Price / Cash Flow36.67 Book Value$9.01 per share Price / Book13.81Miscellaneous Outstanding Shares159,300,000Free Float159,029,000Market Cap$19.82 billion OptionableOptionable Beta1.15 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Jacob Thaysen Ph.D. (Age 49)CEO & Director Comp: $796.63kMs. Carissa L. Rollins (Age 54)Chief Information Officer Comp: $693.52kMr. Charles E. Dadswell Esq. (Age 65)Senior VP & General Counsel Comp: $1.03MDr. Joydeep Goswami M.B.A. (Age 53)Ph.D., Advisor Comp: $843.55kStephanie CamposPresidentMr. Ankur Dhingra (Age 48)Chief Financial Officer Mr. Kevin Carl Pegels (Age 56)Chief of Global Operations Mr. Scott Ericksen (Age 51)VP & Chief Accounting Officer Dr. Steven Barnard Ph.D.Chief Technology OfficerMs. Sallilyn SchwartzVice President of Investor RelationsMore ExecutivesKey CompetitorsRevvityNYSE:PKIBerkeley LightsNASDAQ:BLIAgilent TechnologiesNYSE:AMettler-Toledo InternationalNYSE:MTDWatersNYSE:WATView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 22,328 shares on 9/5/2024Ownership: 0.014%Teachers Retirement System of The State of KentuckyBought 32,173 shares on 8/26/2024Ownership: 0.028%Cetera Investment AdvisersBought 3,767 shares on 8/22/2024Ownership: 0.012%Truist Financial CorpBought 1,075 shares on 8/21/2024Ownership: 0.039%B. Riley Wealth Advisors Inc.Bought 4,579 shares on 8/19/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions Should I Buy Illumina Stock? ILMN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Illumina, Inc.: Illumina's stock price has shown resilience, currently trading at $130.31, with a potential for growth based on recent performance. The company reported positive return on equity of 2.31%, indicating efficient use of shareholder funds to generate earnings. Recent institutional inflows from large investors demonstrate confidence in Illumina's future prospects. With a diverse range of genetic and genomic analysis solutions, Illumina is well-positioned to capitalize on the growing demand for such technologies. Analysts' consensus rating of "Moderate Buy" and an average price target of $151.10 suggest a positive outlook for the company. Cons Investors should be bearish about investing in Illumina, Inc. for these reasons: Illumina's quarterly revenue was down 5.4% compared to the same quarter last year, indicating a potential slowdown in growth. The company had a negative net margin of 28.71%, which may raise concerns about profitability and cost management. The stock's 50-day simple moving average is below the 200-day simple moving average, potentially signaling a bearish trend in the short to medium term. Debt-to-equity ratio of 0.26 may indicate higher financial leverage, increasing the company's risk profile. Market volatility and competition in the genetic and genomic analysis industry could pose challenges to Illumina's market share and growth trajectory. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, August 22, 2024. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com. ILMN Stock Analysis - Frequently Asked Questions How have ILMN shares performed this year? Illumina's stock was trading at $139.24 at the start of the year. Since then, ILMN shares have decreased by 10.7% and is now trading at $124.39. View the best growth stocks for 2024 here. How were Illumina's earnings last quarter? Illumina, Inc. (NASDAQ:ILMN) posted its earnings results on Tuesday, August, 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. The firm's revenue for the quarter was down 5.4% on a year-over-year basis. What is Francis deSouza's approval rating as Illumina's CEO? 496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Illumina have any subsidiaries? The following companies are subsidiaries of Illumina: Grail, Enancio, BlueBee, Edico Genome, Conexio Genomics, GenoLogics, NextBio, and more. Who are Illumina's major shareholders? Illumina's top institutional investors include Baillie Gifford & Co. (3.52%), Bank of New York Mellon Corp (1.91%), Primecap Management Co. CA (1.52%) and Millennium Management LLC (0.93%). Insiders that own company stock include Susan H Tousi, Jacob Thaysen, Aimee L Hoyt, Charles Dadswell, Phillip G Febbo and Alexander Aravanis. View institutional ownership trends. How do I buy shares of Illumina? Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Illumina own? Based on aggregate information from My MarketBeat watchlists, some other companies that Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL) and Salesforce (CRM). This page (NASDAQ:ILMN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Illumina, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Illumina With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ILMN Stock Alerts